Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

  1. Fernandez-Espejo, E.
  2. Caraballo, I.
  3. De Fonseca, F.R.
  4. El Banoua, F.
  5. Ferrer, B.
  6. Flores, J.A.
  7. Galan-Rodriguez, B.
Aldizkaria:
Neurobiology of Disease

ISSN: 0969-9961

Argitalpen urtea: 2005

Alea: 18

Zenbakia: 3

Orrialdeak: 591-601

Mota: Artikulua

DOI: 10.1016/J.NBD.2004.10.015 GOOGLE SCHOLAR
Datuen iturria: Scopus